Dalvance

FDA approves drug to treat MRSA skin infections

The Food and Drug Administration has approved Dalvance (dalbavancin), an antibacterial drug used to treat adults with bacterial skin and skin structure infections. Among them are infections caused by Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and Streptococcus pyogenes.